380 related articles for article (PubMed ID: 33874956)
1. CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSα/ATM-p73 axis in bladder cancer.
Zhang H; Xiao X; Wei W; Huang C; Wang M; Wang L; He Y; Sun J; Jiang Y; Jiang G; Zhang X
Mol Cancer; 2021 Apr; 20(1):70. PubMed ID: 33874956
[TBL] [Abstract][Full Text] [Related]
2. EIF4A3-mediated biogenesis of circSTX6 promotes bladder cancer metastasis and cisplatin resistance.
Wei W; Liu K; Huang X; Tian S; Wang H; Zhang C; Ye J; Dong Y; An Z; Ma X; Wang B; Huang Y; Zhang X
J Exp Clin Cancer Res; 2024 Jan; 43(1):2. PubMed ID: 38163881
[TBL] [Abstract][Full Text] [Related]
3.
Wei W; Sun J; Zhang H; Xiao X; Huang C; Wang L; Zhong H; Jiang Y; Zhang X; Jiang G
Cancer Res; 2021 Dec; 81(24):6142-6156. PubMed ID: 34702726
[TBL] [Abstract][Full Text] [Related]
4. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
Goodspeed A; Jean A; Costello JC
Eur Urol; 2019 Feb; 75(2):242-250. PubMed ID: 30414698
[TBL] [Abstract][Full Text] [Related]
5. HIF-1α-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4.
Yu M; Ozaki T; Sun D; Xing H; Wei B; An J; Yang J; Gao Y; Liu S; Kong C; Zhu Y
J Exp Clin Cancer Res; 2020 Jun; 39(1):108. PubMed ID: 32522234
[TBL] [Abstract][Full Text] [Related]
6. CircUGGT2 facilitates progression and cisplatin resistance of bladder cancer through nonhomologous end-joining pathway.
Lyu F; Huang S; Yan Z; He Q; Liu C; Cheng L; Cong Y; Chen K; Song Y; Xing Y
Cell Signal; 2024 Jul; 119():111164. PubMed ID: 38583745
[TBL] [Abstract][Full Text] [Related]
7. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
[TBL] [Abstract][Full Text] [Related]
8. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
[TBL] [Abstract][Full Text] [Related]
9. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
10. Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression.
Huang X; Li Z; Zhang Q; Wang W; Li B; Wang L; Xu Z; Zeng A; Zhang X; Zhang X; He Z; Li Q; Sun G; Wang S; Li Q; Wang L; Zhang L; Xu H; Xu Z
Mol Cancer; 2019 Mar; 18(1):71. PubMed ID: 30927924
[TBL] [Abstract][Full Text] [Related]
11. Lnc-PTCHD4-AS inhibits gastric cancer through MSH2-MSH6 dimerization and ATM-p53-p21 activation.
Wang J; Mi Y; Sun X; Xue X; Zhao H; Zhang M; Hu B; Bukhari I; Zheng P
Aging (Albany NY); 2023 Nov; 15(22):13558-13578. PubMed ID: 38016120
[TBL] [Abstract][Full Text] [Related]
12. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720
[TBL] [Abstract][Full Text] [Related]
13. Invasion-related circular RNA circFNDC3B inhibits bladder cancer progression through the miR-1178-3p/G3BP2/SRC/FAK axis.
Liu H; Bi J; Dong W; Yang M; Shi J; Jiang N; Lin T; Huang J
Mol Cancer; 2018 Nov; 17(1):161. PubMed ID: 30458784
[TBL] [Abstract][Full Text] [Related]
14. Circular RNA circSLC8A1 acts as a sponge of miR-130b/miR-494 in suppressing bladder cancer progression via regulating PTEN.
Lu Q; Liu T; Feng H; Yang R; Zhao X; Chen W; Jiang B; Qin H; Guo X; Liu M; Li L; Guo H
Mol Cancer; 2019 Jun; 18(1):111. PubMed ID: 31228937
[TBL] [Abstract][Full Text] [Related]
15. ARID1A Inactivation Increases Expression of circ0008399 and Promotes Cisplatin Resistance in Bladder Cancer.
Jiang YK; Shuai YJ; Ding HM; Zhang H; Huang C; Wang L; Sun JY; Wei WJ; Xiao XY; Jiang GS
Curr Med Sci; 2023 Jun; 43(3):560-571. PubMed ID: 37142816
[TBL] [Abstract][Full Text] [Related]
16. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
17. Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR-1270 inhibition.
Yuan W; Zhou R; Wang J; Han J; Yang X; Yu H; Lu H; Zhang X; Li P; Tao J; Wei J; Lu Q; Yang H; Gu M
Mol Oncol; 2019 Jul; 13(7):1559-1576. PubMed ID: 31131537
[TBL] [Abstract][Full Text] [Related]
18. JUND-dependent up-regulation of HMOX1 is associated with cisplatin resistance in muscle-invasive bladder cancer.
Peng Y; Chen Y; Chen S; Wang J; Jiang C; Hou W; Xu C
J Biochem; 2020 Jul; 168(1):73-82. PubMed ID: 32240302
[TBL] [Abstract][Full Text] [Related]
19. circCUL2 regulates gastric cancer malignant transformation and cisplatin resistance by modulating autophagy activation via miR-142-3p/ROCK2.
Peng L; Sang H; Wei S; Li Y; Jin D; Zhu X; Li X; Dang Y; Zhang G
Mol Cancer; 2020 Nov; 19(1):156. PubMed ID: 33153478
[TBL] [Abstract][Full Text] [Related]
20. Circ_0008532 promotes bladder cancer progression by regulation of the miR-155-5p/miR-330-5p/MTGR1 axis.
Chen L; Yang X; Zhao J; Xiong M; Almaraihah R; Chen Z; Hou T
J Exp Clin Cancer Res; 2020 May; 39(1):94. PubMed ID: 32460831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
